University of Texas MD Anderson Cancer Center

Selected news for the hospital/health system - University of Texas MD Anderson Cancer Center, collected since 10/2017. Recent stories appear in bottomlineinc.com and medicalxpress.com. This hospital/health system shares news with Food and Drug Administration, Oncology, Cancer Immunotherapy, National Cancer Institute, Memorial Sloan Kettering Cancer Center and hundreds of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
4/22/2021 Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer | Financial Buzz financialbuzz.com ... thoracic oncology and professor of medicine at the Hospital of the University of Pennsylvania Anne S. Tsao, M.D., professor and section chief of thoracic medical oncology and director of the mesothelioma program at The University of Texas MD Anderson Cancer Center Vinicius Ernani, M.D., Senior Associate Consultant at Mayo Clinic Rupesh Kotecha, M.D., radiation oncologist and chief of radiosurgery at Miami Cancer Institute “In vivo data suggest that using TTFields ...
4/15/2021 Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer stateofaffairs.news ... Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung CancerBoehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim’s KRAS (Kirsten rat sarcoma) and TRAILR2 ...
4/15/2021 Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer digitalconqurer.com Ingelheim, Germany & Houston, United States: Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim’s KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer.The collaboration, launched in ...
4/15/2021 Mutant KRAS and p53 Cooperate to Drive Pancreatic Cancer Metastasis letswinpc.org Mutant KRAS and p53 Cooperate to Drive Pancreatic Cancer Metastasis author Let's Win! Pancreatic Cancer 15 April, 2021 Researchers at The University of Texas MD Anderson Cancer Center have discovered that mutant KRAS and p53, the most frequently mutated genes in pancreatic cancer, interact through the CREB1 protein to promote metastasis and tumor growth. Blocking CREB1 in preclinical models reversed these effects and reduced metastases, suggesting an important new therapeutic ...
4/15/2021 MD Anderson researchers highlight advances in clinical studies at the AACR Annual Meeting 2021 thekatynews.com Early phase clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for patients with RET fusion-positive cancers, high-grade (HGG) and low-grade glioma (LGG) and ovarian cancer. The results, presented today at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, showcase the researchers’ ongoing efforts to advance clinical studies and expand potential indications of approved drugs ...
4/15/2021 Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer Wordpress.com ... treatments and builds on its commitment to delivering first-in-class treatment options to people living with cancerINGELHEIM, Germany & HOUSTON-Wednesday 14 April 2021 [ AETOS Wire ](BUSINESS WIRE) — Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim’s KRAS (Kirsten rat sarcoma) and TRAILR2 ...
4/15/2021 Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer Wordpress.com ... treatments and builds on its commitment to delivering first-in-class treatment options to people living with cancerINGELHEIM, Germany & HOUSTON-Wednesday 14 April 2021 [ AETOS Wire ](BUSINESS WIRE) — Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim’s KRAS (Kirsten rat sarcoma) and TRAILR2 ...
4/15/2021 Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer Wordpress.com ... treatments and builds on its commitment to delivering first-in-class treatment options to people living with cancerINGELHEIM, Germany & HOUSTON-Wednesday 14 April 2021 [ AETOS Wire ](BUSINESS WIRE) — Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim’s KRAS (Kirsten rat sarcoma) and TRAILR2 ...
4/14/2021 Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer financialbuzz.com Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim’s KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer.The collaboration, launched in 2019, has successfully combined MD ...
4/14/2021 MD Anderson and Boehringer Ingelheim expand collaboration to accelerate development of KRAS and TRAILR2 compounds in lung cancer eurekalert.org ... cancer Agreement builds on successful preclinical studies in gastrointestinal cancers through the joint Virtual Research and Development Center University of Texas M. D. Anderson Cancer Center Print E-MailHOUSTON and Ingelheim, Germany ? The University of Texas MD Anderson Cancer Center and Boehringer Ingelheim today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim's KRAS (Kirsten rat sarcoma ...
4/14/2021 MD Anderson and Boehringer Ingelheim expand collaboration to accelerate development of KRAS and TRAILR2 compounds in lung cancer scienmag.com Share Agreement builds on successful preclinical studies in gastrointestinal cancers through the joint Virtual Research and Development CenterHOUSTON and Ingelheim, Germany ? The University of Texas MD Anderson Cancer Center and Boehringer Ingelheim today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim’s KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios ...
4/14/2021 Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer Business Wire ... and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer Apr 14, 2021 8 hrs agoINGELHEIM, Germany & HOUSTON--(BUSINESS WIRE)--Apr 14, 2021--Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim’s KRAS (Kirsten rat sarcoma) and TRAILR2 ...
4/14/2021 expanded-collaboration-MD-Anderson boehringer-ingelheim.com ... from ’s growing portfolio of cancer treatments and builds on its commitment to delivering first-in-class treatment options to people living with cancerIngelheim, Germany and HOUSTON - 14 April 2021 – and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from ’s KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related ...
4/12/2021 AACR: MD Anderson team uncovers new target for blocking mutant KRAS and p53 in pancreatic cancer FierceBiotech ... images/) [CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0)], via Wikimedia Commons)Mutations in the genes KRAS and p53 have been tied to several tumor types, including pancreatic cancer. Scientists at the University of Texas MD Anderson Cancer Center say they have found a critical link between the two abnormal genes and tumor growth in pancreatic cancer—and they’re proposing a way to block it.The MD ...
4/12/2021 Researchers identify surface protein as a new osteosarcoma therapeutic target for antibody-drug conjugates medicalxpress.com by University of Texas M. D. Anderson Cancer Center Credit: CC0 Public DomainA preclinical study led by researchers at The University of Texas MD Anderson Cancer Center shows an antibody-drug conjugate (ADC) targeting surface protein MT1-MMP can act as a guided missile in eradicating osteosarcoma tumor cells without damaging normal tissues. This technology, using precision therapy targeting of cell-surface proteins through a Bicycle toxin conjugate (BTC ...
4/12/2021 Researchers identify surface protein as a new osteosarcoma therapeutic target for antibody-drug conjugates bioengineer.org Novel approach paves the way for vast expansion in the number of drugs targeting osteosarcoma Credit: MD Anderson Cancer CenterAbstract LB008HOUSTON — A preclinical study led by researchers at The University of Texas MD Anderson Cancer Center shows an antibody-drug conjugate (ADC) targeting surface protein MT1-MMP can act as a guided missile in eradicating osteosarcoma tumor cells without damaging normal tissues. This technology, using precision therapy ...
4/11/2021 MD Anderson researchers highlight advances in clinical studies at the AACR Annual Meeting 2021 eurekalert.org ... the AACR Annual Meeting 2021 University of Texas M. D. Anderson Cancer CenterIMAGE: Vivek Subbiah, M.D. view more Credit: MD Anderson Cancer CenterHOUSTON -- Early phase clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for patients with RET fusion-positive cancers, high-grade (HGG) and low-grade glioma (LGG) and ovarian cancer.The results, presented today at the virtual American ...
4/10/2021 Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review - PubMed National Institutes of Health ... Matrisian , Sung Poblete , Laura Rothschild , Chris Sander , Lawrence H Schwartz , Uri Shalit , Sudhir Srivastava , Brian Wolpin Affiliation 1 From the Kenner Family Research Fund, New York, NY Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center , Houston, TX Edward S. Gordon Chair in Medical Oncology Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY Basic and Translational Pancreas Research Program, Department of Medicine ...
4/8/2021 TriSalus Life Sciences and MD Anderson Announce Strategic Research Collaboration to Evaluate Treatment of Solid Tumors | VentureBeat VentureBeat ... immunotherapy Studies to deliver investigational SD-101 directly to the site of the disease employing novel Pressure-Enabled Drug Delivery™ (PEDD™)HOUSTON & DENVER & CHICAGO–(BUSINESS WIRE)–April 8, 2021–The University of Texas MD Anderson Cancer Center and TriSalus Life Sciences ®, an emerging immuno-oncology company committed to transforming outcomes for patients with liver and pancreatic tumors, today announced a strategic research collaboration to evaluate ...
4/8/2021 Exercise Barriers and Adherence to Recommendations in Patients With Cancer - PubMed National Institutes of Health ... 1 , Ariadne Reyes-Garcia 1 2 , Diane D Liu 3 , Janet L Williams 1 , Jack B Fu 1 , Rajesh Yadav 1 , Eduardo Bruera 1 Affiliations 1 Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX. 2 Currently, Psychology Department in Pediatrics, Baylor College of Medicine, Houston, TX. 3 Department of Biostatistics, The University of Texas MD Anderson Cancer Center , Houston, TX. PMID ...